ArticleFrontiers in immunology2026
Neoadjuvant TACE combined with chemo-immunotherapy for giant triple-negative breast cancer: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An Exploratory Study on the Interrelation of Breast Cancer Molecular Phenotypes with Breast Cancer-Associated Adipose Tissues (BCAATs), Neoadjuvant, and Adjuvant Therapies: A Focus on Prognosis and Survival.Medical sciences (Basel, Switzerland) · 2026Article
- Transarterial infusion chemotherapy combined with microwave ablation for inoperable triple-negative breast cancer: a case report.Frontiers in oncology · 2026Article
- Treatment for intermediate and advanced-stage hepatocellular carcinoma: does systemic therapy synergize the therapeutic efficacy of TACE?Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant, ulcerated triple-negative breast cancer (TNBC) presents major therapeutic challenges. We report a 39-year-old woman with a 14.3 cm ulcerated TNBC (cT4bNxM0) who developed infection after intravenous chemotherapy. To achieve rapid local control, a multidisciplinary team elected to perform transarterial chemoembolization (TACE), followed by systemic chemo-immunotherapy using nab-paclitaxel and the PD-1 inhibitor Toripalimab. This multimodal approach led to marked tumor regression and improvement of skin ulceration, enabling curative surgery with modified radical mastectomy and complex reconstruction. Pathology postoperative showed a complete response (Miller-Payne grade 5, ypT0N0M0). This single case suggests that integrating TACE with multimodal neoadjuvant treatment sequences may be feasible in selected patients with extreme presentations of locally advanced TNBC, particularly in patients with extensive tumor burden or poor tolerance to systemic therapy. The approach may enhance local control and elicit synergistic immune activation, offering a potential paradigm for managing extreme TNBC presentations. Further studies are required to clarify the safety, efficacy, and potential immunomodulatory effects of this approach.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.